卡那奴单抗治疗儿童和年轻成人镰状细胞贫血的随机安慰剂对照双盲试验
这项随机双盲多中心2a期研究纳入49例8至20岁镰状细胞贫血患者,按1:1随机接受6次每月300mg皮下卡那奴单抗或安慰剂。预设主要目标(减少疼痛)未达到,但卡那奴单抗组炎症标志物、镰状细胞贫血相关不良事件和严重不良事件、住院次数和住院时长均较安慰剂组减少,疼痛强度、疲劳和缺勤有改善趋势。卡那奴单抗耐受良好,无治疗相关严重不良事件。
要点
- 预设主要目标减少疼痛未达到,但卡那奴单抗组炎症标志物和镰状细胞贫血相关不良事件较安慰剂组减少
- 卡那奴单抗组住院次数和住院时长较安慰剂组减少,疼痛强度、疲劳和缺勤有改善趋势
- 卡那奴单抗耐受良好,无治疗相关严重不良事件,无新安全性信号
核心结论
- 镰状细胞贫血相关的炎症可通过卡那奴单抗选择性阻断IL-1β而减轻,并可能带来治疗获益。
研究设计与样本
- 随机、双盲、多中心2a期研究,纳入49例8至20岁镰状细胞贫血(HbSS或HbSβ0-地中海贫血)患者。
- 患者有急性疼痛发作史,且筛查时超敏C反应蛋白>1.0 mg/L,按1:1随机接受6次每月300 mg皮下卡那奴单抗或安慰剂。
- 49例入组患者中除1例外均接受稳定的背景羟基脲治疗。
主要发现
- 预设主要目标(减少疼痛)未达到。
- 与安慰剂组相比,卡那奴单抗组炎症标志物、镰状细胞贫血相关不良事件和严重不良事件、住院次数和住院时长均减少。
- 卡那奴单抗组疼痛强度、疲劳和缺勤有改善趋势。
- 事后分析显示卡那奴单抗对体重有治疗效应,仅限于儿童患者。
- 卡那奴单抗耐受良好,无治疗相关严重不良事件,无新安全性信号。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Excessive intravascular release of lysed cellular contents from damaged red blood cells (RBCs) in patients with sickle cell anemia (SCA) can activate the inflammasome, a multiprotein oligomer promoting maturation and secretion of proinflammatory cytokines, including interleukin-1β (IL-1β). We hypothesized that IL-1β blockade by canakinumab in patients with SCA would reduce markers of inflammation and clinical disease activity. In this randomized, double-blind, multicenter phase 2a study, patients aged 8 to 20 years with SCA (HbSS or HbSβ0-thalassemia), history of acute pain episodes, and elevated high-sensitivity C-reactive protein >1.0 mg/L at screening were randomized 1:1 to received 6 monthly treatments with 300 mg subcutaneous canakinumab or placebo. Measured outcomes at baseline and weeks 4, 8, 12, 16, 20, and 24 included electronic patient-reported outcomes, hospitalization rate, and adverse events (AEs) and serious AEs (SAEs). All but 1 of the 49 enrolled patients were receiving stable background hydroxyurea therapy. Although the primary objective (prespecified reduction of pain) was not met, compared with patients in the placebo arm, patients treated with canakinumab had reductions in markers of inflammation, occurrence of SCA-related AEs and SAEs, and number and duration of hospitalizations as well as trends for improvement in pain intensity, fatigue, and absences from school or work. Post hoc analysis revealed treatment effects on weight, restricted to pediatric patients. Canakinumab was well tolerated with no treatment-related SAEs and no new safety signal. These findings demonstrate that the inflammation associated with SCA can be reduced by selective IL-1β blockade by canakinumab with potential for therapeutic benefits. This trial was registered at www.clinicaltrials.gov as #NCT02961218.
引用
- Rees DC, Kilinc Y, Unal S, et al. A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia. Blood. 2022. PMID: 35226723. doi:10.1182/blood.2021013674
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。